Questões de Concurso Comentadas sobre inglês para cetro
Foram encontradas 14 questões
Resolva questões gratuitamente!
Junte-se a mais de 4 milhões de concurseiros!
Ano: 2013
Banca:
CETRO
Órgão:
ANVISA
Provas:
CETRO - 2013 - ANVISA - Analista Administrativo - Conhecimentos Gerais - Todas as Áreas
|
CETRO - 2013 - ANVISA - Analista Administrativo - Área 3 |
Q338047
Inglês
Read the text below and choose the alternative that fills in correctly and respectively the blanks.
Ano: 2013
Banca:
CETRO
Órgão:
ANVISA
Prova:
CETRO - 2013 - ANVISA - Analista Administrativo - Conhecimentos Gerais - Todas as Áreas - Prova Anulada |
Q325556
Inglês
According to the formal rule of the English language, choose the alternative that fills in correctly the blank of the sentence below.
“The situation in Europe has created unease among American consumers over ______ or not horse meat might also find its way into the food supply in the United States”.
“The situation in Europe has created unease among American consumers over ______ or not horse meat might also find its way into the food supply in the United States”.
Ano: 2013
Banca:
CETRO
Órgão:
ANVISA
Prova:
CETRO - 2013 - ANVISA - Analista Administrativo - Conhecimentos Gerais - Todas as Áreas - Prova Anulada |
Q325554
Inglês
Read the sentence below
“Botox's sales grew 1,407% and by 2007, total Botox sales exceeded $500 million. More than 70% of that was for unapproved uses.”
It is correct to affirm that the underlined word refers to
“Botox's sales grew 1,407% and by 2007, total Botox sales exceeded $500 million. More than 70% of that was for unapproved uses.”
It is correct to affirm that the underlined word refers to
Ano: 2013
Banca:
CETRO
Órgão:
ANVISA
Prova:
CETRO - 2013 - ANVISA - Analista Administrativo - Conhecimentos Gerais - Todas as Áreas - Prova Anulada |
Q325553
Inglês
Read the sentence below and choose the alternative that correctly links the underlined words to the nouns they refer to.
An FDA advisory panel, (I) which gave preliminary approval to Allergan's application, wasn't entirely happy with the company's data supporting (II) its safety and efficacy claims for the Lap-Band— (III) its own 149-patient study and six other studies, at least three of (IV) which conducted by researchers with financial links to Allergan.
An FDA advisory panel, (I) which gave preliminary approval to Allergan's application, wasn't entirely happy with the company's data supporting (II) its safety and efficacy claims for the Lap-Band— (III) its own 149-patient study and six other studies, at least three of (IV) which conducted by researchers with financial links to Allergan.